We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Circulating CD89-IgA complex does not predict deterioration of kidney function in Korean patients with IgA nephropathy.
- Authors
Jhee, Jong Hyun; Kang, Hye-Young; Wu, Meiyan; Nam, Bo Young; Chang, Tae-Ik; Jung, Su-Young; Park, Seohyun; Kim, Hyoungnae; Yun, Hae-Ryong; Kee, Youn Kyung; Yoon, Chang-Yun; Park, Jung Tak; Yoo, Tae-Hyun; Kang, Shin-Wook; Han, Seung Hyeok
- Abstract
Background: Soluble CD89 (sCD89)-IgA complex plays a key role in the pathogenesis of IgA nephropathy (IgAN). However, there is a lack of evidence supporting this complex as a good biomarker for disease progression. This study aimed to evaluate the usefulness of sCD89-IgA complex for risk stratification of IgAN. Methods: A total of 326 patients with biopsy-proven IgAN were included. sCD89-IgA complex was measured by sandwich-enzyme-linked immunosorbent assay. The study endpoints were a 30% decline in estimated glomerular filtration rate (eGFR). Results: sCD89-IgA complex levels were inversely and weakly associated with eGFR at the time of biopsy (r = - 0.12, p = 0.03). However, the significance between the two factors was lost in the multivariate linear regression after adjustment of clinical factors (ß = 0.35, p = 0.75). In a multivariate Cox model, the highest (hazard ratio [HR], 0.75; 95% confidence interval [CI], 0.35-1.61; p = 0.45) and middle (HR, 0.93; 95% CI, 0.46-1.89; p = 0.84) tertiles of sCD89-IgA complex levels were not associated with an increased risk of developing a 30% decrease in eGFR. Furthermore, the decline rates in eGFR did not differ between groups and C-statistics revealed that the sCD89-IgA complex were not superior to clinical factors in predicting disease progression. Conclusions: This study found no association between sCD89-IgA complex levels and disease progression in IgAN. Although sCD89 can contribute to the formation of immune complexes, our findings suggest that the sCD89- IgA level is not a good predictor of adverse outcomes and has limited clinical utility as a biomarker for risk stratification in IgAN.
- Subjects
IMMUNOGLOBULIN A; IGA glomerulonephritis; TUMOR markers; IMMUNOASSAY; GLOMERULAR filtration rate
- Publication
Clinical Chemistry & Laboratory Medicine, 2018, Vol 56, Issue 1, p75
- ISSN
1434-6621
- Publication type
Article
- DOI
10.1515/cclm-2017-0090